Name /BELX Bio-Pharmaceutical
Address /Rm. 536, Bldg. 52, 195, Sec. 4, Chung Hsing Rd., Chutung, Hsinchu, 31040, Taiwan, ROC
Name /Ching-Yuan Ian Lee
Title /Chief business officer
Telephone /(Work) +886-3-5910151 ext. 208 Ms. Lai
BELX Biopharmaceuticals is a research and development biotech company, aiming at developing botanical new drugs to treat tumors and chronic liver diseases. The company is playing a leadership role in Taiwan and aspires to contribute its best efforts to improve the medical and healthcare benefits for humankind.
BEL-X is a botanical new drug that has entered the clinical stage, comes from a single plant of homologous origin. Based on its more than 1,000 years of experience in human use, the safety of this drug is consolidated. BEL-X's research can be dated back since 2000, a group of botanical drug experts in ITRI (Industrial Technology Research Institute) devoted themselves in a government funded project. After more than 20 years of research and development, the team has developed a safe and effective oral dosage form by using modern scientific methods to extract the active ingredients, confirming the mechanism of action, and refining the high quality manufacturing process. Currently, BEL-X has completed clinical phase I trials approved by the U.S. FDA and Taiwan TFDA, and the trial was conducted at the Clinical Trial Center of National Taiwan University Hospital and National Cheng Kung University Hospital, with satisfactory results in terms of safety and initial efficacy in subjects with various refractory solid tumor diseases.
Name /Chou Yu Kuo